Drug class
Adeno-associated virus serotype 2 (AAV2) gene therapy delivering the DDC gene
Mechanism of action
A recombinant AAV2 vector delivers a functional copy of the DDC gene encoding aromatic L-amino acid decarboxylase (AADC) to cells in the putamen. The transduced cells produce AADC, supporting conversion of L-DOPA to dopamine in patients with AADC deficiency.
General use cases
- Treatment of adult and paediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency under the applicable product authorisation; age criteria and specialist administration requirements are label-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
